OliX PharmaceuticalsInc
OliX Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. The company's products pipeline includes OLX101A for skin scar; OLX104C for androgenic alopecia; OLX301A for age-related macular degeneration; OLX702A for metabolic dysfunction-associated steatohepatitis; OLX703A for hepati… Read more
OliX PharmaceuticalsInc - Asset Resilience Ratio
OliX PharmaceuticalsInc (226950) has an Asset Resilience Ratio of 61.19% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how OliX PharmaceuticalsInc's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down OliX PharmaceuticalsInc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩114.17 Billion | 61.19% |
| Total Liquid Assets | ₩114.17 Billion | 61.19% |
Asset Resilience Insights
- Very High Liquidity: OliX PharmaceuticalsInc maintains exceptional liquid asset reserves at 61.19% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
OliX PharmaceuticalsInc Industry Peers by Asset Resilience Ratio
Compare OliX PharmaceuticalsInc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for OliX PharmaceuticalsInc (2016–2024)
The table below shows the annual Asset Resilience Ratio data for OliX PharmaceuticalsInc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 11.96% | ₩8.52 Billion | ₩71.25 Billion | -1.59pp |
| 2023-12-31 | 13.55% | ₩13.93 Billion | ₩102.83 Billion | -33.09pp |
| 2022-12-31 | 46.64% | ₩61.87 Billion | ₩132.65 Billion | -10.77pp |
| 2021-12-31 | 57.41% | ₩49.76 Billion | ₩86.67 Billion | -29.27pp |
| 2020-12-31 | 86.68% | ₩68.11 Billion | ₩78.58 Billion | +42.54pp |
| 2019-12-31 | 44.14% | ₩19.95 Billion | ₩45.21 Billion | -7.65pp |
| 2018-12-31 | 51.79% | ₩28.81 Billion | ₩55.64 Billion | -0.51pp |
| 2017-12-31 | 52.30% | ₩11.32 Billion | ₩21.64 Billion | -10.30pp |
| 2016-12-31 | 62.60% | ₩9.48 Billion | ₩15.15 Billion | -- |